NOXXON Pharma announces appointment of Dr. Walter Wenninger as Chairman of the Board
This release was saved as a PDF file. Please click on the "view PDF" link to display this report.
You need the free Adobe Reader in order to display this release.Download Adobe Reader
Noxxon Pharma AG
Based on one of best protected technology platforms in the industry, NOXXON Pharma AG develops biostable aptamers, novel substances using mirror image nucleic acids. These so-called Spiegelmers® (the German word "Spiegel" means mirror) are highly specific for the pharmacologically relevant target for which they were selected. Thanks to their structural characteristics, Spiegelmers® are extremely resistant to degradation and not immunogenic - a new generation of improved therapeutics.